对VAD方案的早期化疗敏感性可预测多发性骨髓瘤自体干细胞移植后的良好预后。
Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma.
作者信息
Patriarca Francesca, Sperotto Alessandra, Filì Carla, Zaja Francesco, Prosdocimo Simonetta, Fanin Renato
出版信息
Haematologica. 2002 Jul;87(7):779-81.
PMID:12091134
Abstract
We report that early chemosensitivity, defined by a greater than 50% reduction of M-component and plasma-cell marrow infiltration, after 2 cycles of VAD was correlated with a favorable outcome following autologous stem cell transplantation in 46 patients with newly diagnosed multiple myeloma submitted to high-dose therapy.
摘要
我们报告称，在46例接受大剂量治疗的新诊断多发性骨髓瘤患者中，2个周期的VAD治疗后，早期化学敏感性（定义为M成分减少超过50%和浆细胞骨髓浸润减少）与自体干细胞移植后的良好预后相关。
相似文献
1
Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma.
Haematologica. 2002 Jul;87(7):779-81.
2
Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
Bone Marrow Transplant. 1999 Feb;23(4):317-22. doi: 10.1038/sj.bmt.1701574.
3
Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.
4
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Cancer. 2008 Jan 1;112(1):129-35. doi: 10.1002/cncr.23145.
5
Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma.
Bone Marrow Transplant. 2000 Jul;26(1):45-50. doi: 10.1038/sj.bmt.1702445.
6
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Am J Hematol. 2007 Dec;82(12):1071-5. doi: 10.1002/ajh.21038.
7
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
J Clin Oncol. 2010 Oct 20;28(30):4621-9. doi: 10.1200/JCO.2009.27.9158. Epub 2010 Sep 7.
8
Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512.
9
Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma.
Intern Med J. 2004 Sep-Oct;34(9-10):576-8. doi: 10.1111/j.1445-5994.2004.00689.x.
10
Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?
Eur J Haematol. 2006 Sep;77(3):239-44. doi: 10.1111/j.1600-0609.2006.00701.x. Epub 2006 Jul 19.
Zotero 插件